Skip to main content
SpringerLink
Log in

In-silico structural analysis of the influenza A subtype H7N9 neuraminidase and molecular docking with different neuraminidase inhibitors

  • Original Article
  • Published:
VirusDisease Aims and scope Submit manuscript

Abstract

Human infection with H7 influenza subtypes usually resulted in mild disease with a rare mortalities, however, human infection with the avian low pathogenic H7N9 influenza virus resulted in about 38.6 % human fatality. Due to the new cross-species barrier of this virus subtype, there is an urgent need to better understand the susceptibility to commercially available antivirals and their relation to the structural changes of the viral neuraminidase. Neuraminidases derived from 2013 H7N9, H5N1 and H1N1 were subjected to a structural analysis of their catalytic and framework binding sites. The modeling structure of selected neuraminidases from H7N9 and influenza A subtypes were solved and the docking studies with oseltamivir, zanamivir, laninamivir and peramivir were conducted. The active site residues that are responsible for both binding and cleavage of the terminally linked sialic acid receptors were found conserved. Docking studies with oseltamivir, zanamivir, laninamivir and peramivir revealed that the laninamivir and peramivir showed superior energy binding activities in comparison to the commonly used oseltamivir and zanamivir. The results presented in the current study provide data that are useful for the future treatment of different influenza A subtypes including the recently emerged H7N9.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Cardona CJ, Xing Z, Sandrock CE, Davis CE. Avian influenza in birds and mammals. Comp Immunol Microbiol Infect Dis. 2009;32(4):255–73.

    Article  PubMed  Google Scholar 

  2. Chong AK, Pegg MS, Taylor NR, von Itzstein M. Evidence for a sialosyl cation transition-state complex in the reaction of sialidase from influenza virus. Eur J Biochem. 1992;207(1):335–43.

    Article  CAS  PubMed  Google Scholar 

  3. Colman PM. New antivirals and drug resistance. Annu Rev Biochem. 2009;78:95–118.

    Article  CAS  PubMed  Google Scholar 

  4. Du QS, Wang SQ, Chou KC. Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases. Biochem Biophys Res Commun. 2007;354:634–40.

    Article  PubMed  Google Scholar 

  5. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med. 2013;. doi:10.1056/NEJMoa1304459.

    Google Scholar 

  6. Gubareva LV. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res. 2004;103:199–203.

    Article  CAS  PubMed  Google Scholar 

  7. Gubareva LV, Webster RG, Hayden FG. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother. 2001;45:3403–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Horimoto T, Kawaoka Y. Pandemic threat posed by avian influenza A viruses. Clin Microbiol Rev. 2001;14(1):129–49.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, Barr IG. Susceptibility of highly pathogenic A (H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res. 2007;73:228–31.

    Article  CAS  PubMed  Google Scholar 

  10. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364:759–65.

    Article  CAS  PubMed  Google Scholar 

  11. Kohno SH, Kida H, Mizuguchi M, Shimada J. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother. 2010;54(11):4568–74.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Koopmans M, Wilbrink B, Conyn M, Natrop G, van der Nat H, Vennema H, et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet. 2004;363(9409):587–93.

    Article  PubMed  Google Scholar 

  13. Kumar S, Tamura K, Jakobsen IB, Nei M. Molecular evolutionary genetics analysis software. Bioinformatics. 2001;17:1244–5.

    Article  CAS  PubMed  Google Scholar 

  14. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KH, et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature. 2005;437(7062):1108.

    Article  CAS  PubMed  Google Scholar 

  15. Le MT, Wertheim HF, Nguyen HD, Taylor W, Hoang PV, Vuong CD, et al. Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in northern Vietnam. PLoS ONE. 2008;3(10):e3339.

    Article  PubMed Central  PubMed  Google Scholar 

  16. McKimm-Breschkin JL. Resistance of influenza viruses to neuraminidase inhibitors-a review. Antiviral Res. 2000;47:1–17.

    Article  CAS  PubMed  Google Scholar 

  17. Murphy BR, Webster RG. Orthomyxoviruses. Fields Virology. Philadelphia: Lippincott-Raven; 1996.

    Google Scholar 

  18. Russell J, Haire F, Stevens J, Collins J, Lin P, Blackburn M, et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature. 2006;443:45–9.

    Article  CAS  PubMed  Google Scholar 

  19. Shobugawa Y, Saito R, Sato I, Kawashima T, Dapat C, Dapat IC, et al. Clinical effectiveness of neuraminidase inhibitors–oseltamivir, zanamivir, laninamivir, and peramivir–for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan. J Infect Chemother. 2012;18(6):858–64.

    Article  CAS  PubMed  Google Scholar 

  20. Tong S, Li Y, Rivailler P, Conrardy C, Castillo DA, Chen LM, et al. A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci USA. 2012;109(11):4269–74.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Tong S, Zhu X, Li Y, Shi M, Zhang J, Bourgeois M, et al. New world bats harbor diverse influenza A viruses. PLoS Pathog. 2013;9(10):e1003657.

    Article  PubMed Central  PubMed  Google Scholar 

  22. von Itzstein M. The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov. 2007;6:967–74.

    Article  Google Scholar 

  23. Wang K, Shun-Shin M, Gill P, Perera R, Harnden A. Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). Cochrane Database Syst Rev. 2012;18(4):CD002744.

    Google Scholar 

  24. Watanabe A, Chang SC, Kim MJ, Chu DWS, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial. Clin Infect Dis. 2010;51(10):1167–75.

    Article  CAS  PubMed  Google Scholar 

  25. Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother. 2009;53(1):186–92.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Yen HL, Hoffmann E, Taylor G, Scholtissek C, Monto AS, Webster RG, et al. Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J Virol. 2006;80(17):8787–95.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicinal Chemistry, National Research Center, Dokki, Cairo, Egypt

    Ahmad F. Eweas

  2. Department of Pharmaceutical Chemistry, College of Pharmacy, Taif University, Al-Taif, 21944, Saudi Arabia

    Ahmad F. Eweas

  3. Virology Department, Faculty of Veterinary Medicine, Beni-Suef University, Beni-Suef, 62511, Egypt

    Ahmed S. Abdel-Moneim

  4. Department of Microbiology, Virology Division, College of Medicine, Taif University, Al-Taif, 21944, Saudi Arabia

    Ahmed S. Abdel-Moneim

Authors
  1. Ahmad F. Eweas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ahmed S. Abdel-Moneim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ahmed S. Abdel-Moneim.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Structure of known NA inhibitors (JPEG 49 kb)

Supplementary material 2 (DOC 51 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eweas, A.F., Abdel-Moneim, A.S. In-silico structural analysis of the influenza A subtype H7N9 neuraminidase and molecular docking with different neuraminidase inhibitors. VirusDis. 26, 27–32 (2015). https://doi.org/10.1007/s13337-014-0245-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13337-014-0245-5

Keywords

Search

Navigation